Compare Bausch + Lomb Corp. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROCE of 2.16%
- The company has been able to generate a Return on Capital Employed (avg) of 2.16% signifying low profitability per unit of total capital (equity and debt)
2
The company declared negative results in Mar'25 after positive results in Dec'24
3
Risky -
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 6,113 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.72
-3.33%
0.95
Revenue and Profits:
Net Sales:
1,278 Million
(Quarterly Results - Jun 2025)
Net Profit:
-58 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.79%
0%
6.79%
6 Months
-17.77%
0%
-17.77%
1 Year
13.12%
0%
13.12%
2 Years
-8.17%
0%
-8.17%
3 Years
20.68%
0%
20.68%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Bausch + Lomb Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
258.24%
EBIT Growth (5y)
133.59%
EBIT to Interest (avg)
-4.51
Debt to EBITDA (avg)
5.41
Net Debt to Equity (avg)
0.73
Sales to Capital Employed (avg)
0.40
Tax Ratio
8.95%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
17.82%
ROCE (avg)
2.16%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.65
EV to EBIT
56.08
EV to EBITDA
14.88
EV to Capital Employed
0.80
EV to Sales
1.81
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1.42%
ROE (Latest)
-3.98%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 19 Schemes (0.96%)
Foreign Institutions
Held by 52 Foreign Institutions (4.12%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
1,278.00
1,216.00
5.10%
Operating Profit (PBDIT) excl Other Income
118.00
150.00
-21.33%
Interest
131.00
105.00
24.76%
Exceptional Items
-33.00
-15.00
-120.00%
Consolidate Net Profit
-58.00
-148.00
60.81%
Operating Profit Margin (Excl OI)
8.60%
32.90%
-2.43%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 5.10% vs 17.49% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 60.81% vs -410.34% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,791.00
4,146.00
15.56%
Operating Profit (PBDIT) excl Other Income
642.00
586.00
9.56%
Interest
412.00
296.00
39.19%
Exceptional Items
-61.00
-102.00
40.20%
Consolidate Net Profit
-305.00
-248.00
-22.98%
Operating Profit Margin (Excl OI)
43.00%
49.20%
-0.62%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 15.56% vs 10.03% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -22.98% vs -1,753.33% in Dec 2023
About Bausch + Lomb Corp. 
Bausch + Lomb Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






